Novabay Pharmaceuticals Inc RSI
Qual é o RSI de Novabay Pharmaceuticals Inc?
O RSI de Novabay Pharmaceuticals Inc é 40.42
Qual é a definição de RSI?
O índice de força relativa (RSI 14) é um indicador de momento que compara a magnitude de ganhos e perdas em um período de tempo especificado para medir a velocidade e a variação dos movimentos de preço de um título.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI de empresas na Setor Health Care em NYSEMKT em comparação com Novabay Pharmaceuticals Inc
O que Novabay Pharmaceuticals Inc faz?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Empresas com rsi semelhantes a Novabay Pharmaceuticals Inc
- Ad4 Capital Corp tem RSI de 40.41
- Discovery Communications tem RSI de 40.41
- Virat Crane Industries tem RSI de 40.41
- Alexco Resource Corp tem RSI de 40.41
- CryoPort Inc tem RSI de 40.41
- Skyworks Solutions tem RSI de 40.41
- Novabay Pharmaceuticals Inc tem RSI de 40.42
- G-Resources tem RSI de 40.43
- Dicks Sporting Goods tem RSI de 40.43
- Hexcel tem RSI de 40.43
- Strabag SE tem RSI de 40.43
- Ling Yui tem RSI de 40.44
- Gibb River Diamonds tem RSI de 40.44